Guerbet LLC
USA

Related Content

Technology
FDA Approves First Macrocyclic and Ionic Gadolinium-Contrast Agent for MRI

March 21, 2013 -- Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate ...

Home March 22, 2013
arrow
Dotarem Guebert LLC FDA NDA Approval Contrast Media MRI Systems
News
FDA Committee Recommends Approval of Guerbet’s Macrocyclic, Ionic Gadolinium MRI Contrast Agent

February 20, 2013 — Guerbet announced that the Medical Imaging Drugs Advisory Committee to U.S. Food and Drug ...

Home February 20, 2013
arrow
Technology
Oxilan Offers Contrast Media for Peripheral Procedures

Oxilan (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity. Its reported ...

Home October 28, 2008
arrow
Technology
Contrast Agent Lowers Side Effects

Guerbet will feature its Oxilan (ioxilan) injection, a contrast agent that is a nonionic low-viscous and low-osmolar ...

Home November 14, 2007
arrow
News
Guerbet Highlights X-Ray Agent, Oxilan

October 18, 2007 - Guerbet will feature at TCT 2007 its x-ray contrast agent, Oxilan (ioxilan) injection, a contrast ...

Home October 17, 2007
arrow
Technology
Guerbet’s Oxilan Wins Frost & Sullivan Award for Contrast Media with Low Side Effects

Guerbet’s flagship X-ray contrast agent, Oxilan (ioxilan) injection, is a contrast agent that is a nonionic, low-viscous ...

Home September 05, 2007
arrow
Technology
OXILAN Offers Contrast Media for Peripheral Procedures

OXILAN (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity. Its reportedly ...

Home August 29, 2006
arrow
Comparison Charts
Radiation Dose Monitoring
Home
arrow
Comparison Charts
MRI Contrast Agents
Home
arrow
Comparison Charts
Contrast Media Injectors
Home
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now